Overview

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

Objectives - Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib - Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib

Phase:

Phase 1

Details

Lead Sponsor:

FibroGen

Treatments:

Antibodies, Monoclonal
Erlotinib Hydrochloride
Gemcitabine